S100B protein: a target for an antiasthenic drug with antioxidant activity

N.Yu. Shimokhina¹, M.M. Petrova¹, L.A. Skipetrova², R.A. Cheremin², N.S. Mut’ev¹, P.R. Kamchatnov³

¹Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk

²Center for Speech Disorders and Neurorehabilitation, Moscow

³Pirogov Russian National Research Medical University, Moscow

The paper highlights modern concepts of asthenic syndrome in patients with chronic non-communicable diseases (e.g., cardiovascular diseases, bronchopulmonary diseases, diabetes mellitus, malignant neoplasms, etc.). Data on the brain-specific protein S100B role in pathogenesis of asthenic syndrome of various origin are reported. Results of preclinical studies of technologically processed S100B antibodies-based drugs are reviewed. The information indicates that their antioxidant effect (prevention or limitation of hypoxic hyperactivation of lipid peroxidation processes) is comparable or higher than that of a reference drug (ethylmethylhydroxypyridine succinate). Randomized controlled trials of efficiency and safety of technologically processed S100B antibodies-based drugs demonstrated strong antiasthenic and antioxidant effects (i. e., recovered activity of a predominantly endogenous antioxidant system in patients with cerebral atherosclerosis). Thus, Prospekta administration leads to a significant regression of asthenic symptoms and management of oxidative stress in patients with chronic non-communicable diseases.

Keywords: asthenic syndrome, weakness, fatigue, performance degradation, antioxidant effect, S100B, Prospekta.

For citation: Shimokhina N.Yu., Petrova M.M., Skipetrova L.A., Cheremin R.A., Mut’ev N.S., Kamchatnov P.R. S100B protein: a target for an antiasthenic drug with antioxidant activity. RMJ. 2025;3:42–45. DOI: 10.32364/2225-2282-2025-3-8